Substitute for form 1449A/PTO & 1449B/PTO Complete if Known **Application Number** 09/961,086 **FOURTH INFORMATION DISCLOSURE Filing Date** September 21, 2001 STATEMENT BY APPLICANT Ross, Douglas D. et. al. **First Named Inventor Examiner Name** Susan Ungar (use as many sheets as necessary) Sheed **Attorney Docket Number** 028754-039 of

APR 1 3 2004

\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	U.S. PATENT DOCUMENTS						
Transchoer Initials	Document Kind Code Number (if known)		Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)			
	· · · · · · · · · · · · · · · · · · ·						

	FOREIGN PATENT DOCUMENTS								
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation				
					Yes	No			
					· · · ·				
		ļ							
					ļ				
			<u> </u>						
					1				

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
qu	CHANG-JIE CHEN, ET AL., "Genomic Organization of the Human Multidrug Resistance (MDR1) Gene and Origin of P-glycoproteins", The Journal of Biological Chemistry, Vol. 265(1):506-514 (1999)					
	A. AUSTIN DOYLE ET AL., "Characterization of a 95 Kilodalton Membrane Glycoprotein Associated with Multi- Drug Resistance", Int. J. Cancer: 62:593-598 (1995)					
	L.A. DOYLE ET AL., "Expression of a 95 kDa Membrane Protein is Associated with Low Daunorubicin Accumulation in Leukaemic Blast Cells", Br. J. Cancer 1995 Jan.;71(1)52-8					
. \ ,	D.D.ROSS ET AL., "Expression of Multidrug Resistance-Associated Protein (MRP) mRNA in Blast Cells from Acute Myeloid Leukemia (AML) Patients", Leukemia (1996) 10, 48-55					
Y	D.D.ROSS ET AL., "Susceptibility of Idarubincin, Daunorubicin, and Their C-13 Alcohol Metabolites to Transport-Mediated Multidrug Resistance", Biochemical Pharmacology, Vol. 50(10):1673-1683 (1995)					

Examiner Signature Date Considered 1//3/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.